Digital movie analysis for quantification of beating frequencies, chronotropic effects, and beating areas in cardiomyocyte cultures

Assay and Drug Development Technologies

Volumn 6, Issue 3, 2008, Pages 375-385

  Stummann, Tina C ^a   Wronski, Mateusz ^b   Sobanski, Tomasz ^a   Kumpfmueller, Benjamin ^a,c   Hareng, Lars ^a,d   Bremer, Susanne ^a   Whelan, Maurice P ^a  

^a JOINT RESEARCH CENTRE   (Italy)

^b WROCLAW UNIVERSITY OF TECHNOLOGY   (Poland)

^c University of Bath   (United Kingdom)

^d BASF SE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ISOPRENALINE;

ANIMAL CELL; ARTICLE; CHRONOTROPISM; COMPUTER PROGRAM; CONTROLLED STUDY; DIGITAL IMAGING; ELECTRIC FIELD; ELECTRIC POTENTIAL; EMBRYONIC STEM CELL; HEART BEAT; HEART CELL CULTURE; HEART CONTRACTION; MOUSE; NONHUMAN; ANIMAL; CELL LINE; CYTOLOGY; DRUG EFFECT; HEART MUSCLE CELL; HEART RATE; PHYSIOLOGY;

ANIMALS; CELL LINE; EMBRYONIC STEM CELLS; HEART RATE; ISOPROTERENOL; MICE; MYOCARDIAL CONTRACTION; MYOCYTES, CARDIAC; SOFTWARE;

EID: 51149104844     PISSN: 1540658X     EISSN: None     Source Type: Journal    
DOI: 10.1089/adt.2008.129     Document Type: Article

References (41)

1. Kaushik V, Leon AR, Forrester JS Jr, Trohman RG: Bradyarrhythmias, temporary and permanent pacing. Crit Care Med 2000;28:N121-N128.
2. Lasser KE, Allen PD, Woolhandler SJ, Himmelstein DU, Wolfe SM, Bor DH: Timing of new black box warnings and withdrawals for prescription medications. JAMA 2002;287:2215-2220.
3. Lexchin J: Drug withdrawals from the Canadian market for safety reasons, 1963-2004. CMAJ 2005;172:765-767.
4. Pugsley MK: Methods in Pharmacology and Toxicology: Cardiac Drug Development Guide. Humana Press, Clifton, NJ, 2003.
5. EMEA: ICH Topic S7B The Nonclinical Evaluation of the Potential for Delayed Ventricular Repolarization (QT Interval Prolongation) by Human Pharmaceuticals. EMEA, London, 2005. http://www.emea.europa.eu/pdfs/human/ich/ 042302en.pdf (accessed August 8, 2007).
6. th ed. McGraw-Hill, New York, 2008.
7. EMEA: ICH Topic S7A Safety Pharmacology Studies for Human Pharmaceuticals. EMEA, London, 2001. http://www.emea.europa.eu/pdfs/human/ich/ 053900en.pdf (accessed August 8, 2007).
8. DiMasi JA: The value of improving the productivity of the drug development process: faster times and better decisions. Pharmacoeconomics 2002;20(Suppl 3):1-10.
9. Friedrichs GS, Patmore L, Bass A: Non-clinical evaluation of ventricular repolarization (ICH S7B): results of an interim survey of international pharmaceutical companies. J Pharmacol Toxicol Methods 2005;52:6-11.
10. Meyer T, Sartipy P, Blind F, Leisgen C, Guenther E: New cell models and assays in cardiac safety profiling. Expert Opin Drug Metab Toxicol 2007;3:507-517.
11. Bass AS, Tomaselli G, Bullingham R III, Kinter LB: Drugs effects on ventricular repolarization: a critical evaluation of the strengths and weaknesses of current methodologies and regulatory practices. J Pharmacol Toxicol Methods 2005;52:12-21.
12. Harary I, Wallace G, Bristol G: A video-computer for the chronotropic and inotropic measurements of the beating of cultured heart cells. Cytometry 1983;3:367-375.
13. Gervais-Pingot V, Legrand JJ, Nasr G, Schoevaert D: In vitro quantification by image analysis of inotropic and chronotropic effects of drugs on cultures of cardiac myocytes. Cell Biol Toxicol 1994;10:297-300.
14. Reppel M, Boettinger C, Hescheler J: Beta-adrenergic and muscarinic modulation of human embryonic stem cell-derived cardiomyocytes. Cell Physiol Biochem 2004;14:187-196.
15. Capi O, Gepstein L: Myocardial regeneration strategies using human embryonic stem cell-derived cardiomyocytes. J Control Release 2006;116:211-218.
16. Boheler KR, Crider DG, Tarasova Y, Maltsev VA: Cardiomyocytes derived from embryonic stem cells. Methods Mol Med 2005;108:417-435.
17. Maltsev VA, Rohwedel J, Hescheler J, Wobus AM: Embryonic stem cells differentiate in vitro into cardiomyocytes representing sinusnodal, atrial and ventricular cell types. Mech Dev 1993;44:41-50.
18. Banach K, Halbach MD, Hu P, Hescheler J, Egert U: Development of electrical activity in cardiac myocyte aggregates derived from mouse embryonic stem cells. Am J Physiol Heart Circ Physiol 2003;284:H2114-H2123.
19. Kehat I, Khimovich L, Caspi O, Gepstein A, Shofti R, Arbel G, et al.: Electromechanical integration of cardiomyocytes derived from human embryonic stem cells. Nat Biotechnol 2004;22:1282-1289.
20. Spielmann H, Scholz G: INVITTOX Protocol 113. Embryonic Stem Cell Test (EST). ECVAM SIS database of the European Commission, 2002. http://ecvam-sis. jrc.it/IP1685/published/indexed_113.html (accessed August 18, 2006).
21. Genschow E, Spielmann H, Scholz G, Pohl I, Seiler A, Clemann N, et al.: Validation of the embryonic stem cell test in the international ECVAM validation study on three in vitro embryotoxicity tests. Altern Lab Anim 2004;32:209-244.
22. Hakkoum D, Stoppini L, Muller D: Interleukin-6 promotes sprouting and functional recovery in lesioned organotypic hippocampal slice cultures. J Neurochem 2007;100:747-757.
23. Waldeck B: Beta-adrenoceptor agonists and asthma - 100 years of development. Eur J Pharmacol 2002;445:1-12.
24. Pillekamp F, Reppel M, Dinkelacker V, Duan Y, Jazmati N, Bloch W, et al.: Establishment and characterization of a mouse embryonic heart slice preparation. Cell Physiol Biochem 2005;16:127-132.
25. Halbach M, Egert U, Hescheler J, Banach K: Estimation of action potential changes from field potential recordings in multicellular mouse cardiac myocyte cultures. Cell Physiol Biochem 2003;13:271-284.
26. Ali NN, Xu X, Brito-Martins M, Poole-Wilson PA, Harding SE, Fuller SJ: Beta-adrenoceptor subtype dependence of chronotropy in mouse embryonic stem cell-derived cardiomyocytes. Basic Res Cardiol 2004;99:382-391.
27. Molenaar P, Parsonage WA: Fundamental considerations of beta-adrenoceptor subtypes in human heart failure. Trends Pharmacol Sci 2005;26:368-375.
28. 2+ channel blockers. Differentiation 1991;48:173-182.
29. 2+ current in the early stages of cardiomyocyte development. Circ Res 1999;84:136-145.
30. Harding SE, Ali NN, Brito-Martins M, Gorelik J: The human embryonic stem cell-derived cardiomyocyte as a pharmacological model. Pharmacol Ther 2007;113:341-353.
31. Mummery C: Cardiomyocytes from human embryonic stem cells: more than heart repair alone. Bioessays 2007;29:572-579.
32. Porter GA Jr, Rivkees SA: Ontogeny of humoral heart rate regulation in the embryonic mouse. Am J Physiol Regul Integr Comp Physiol 2001;281:R401-R407.
33. Chen FM, Yamamura HI, Roeske WR: Ontogeny of mammalian myocardial beta-adrenergic receptors. Eur J Pharmacol 1979;58:255-264.
34. Bremer S, Hartung T: The use of embryonic stem cells for regulatory developmental toxicity testing in vitro - the current status of test development. Curr Pharm Des 2004;10:2733-2747.
35. Genschow E, Spielmann H, Scholz G, Seiler A, Brown N, Piersma A, et al.: The ECVAM International Validation Study on In Vitro Embryotoxicity Tests: results of the definitive phase and evaluation of prediction models. European Centre for the Validation of Alternative Methods. Altern Lab Anim 2002;30:151-176.
36. Pellizzer C, Bello E, Adler S, Hartung T, Bremer S: Detection of tissue-specific effects by methotrexate on differentiating mouse embryonic stem cells. Birth Defects Res B Dev Reprod Toxicol 2004;71:331-341.
37. Stummann TC, Hareng L, Bremer S: Embryotoxicity hazard assessment of methylmercury and chromium using embryonic stem cells. Toxicology 2007;242:130-134.
38. Lawrence CL, Pollard CE, Hammond TG, Valentin JP: Nonclinical proarrhythmia models: predicting torsades de pointes. J Pharmacol Toxicol Methods 2005;52:46-59.
39. Hoffmann P, Warner B: Are hERG channel inhibition and QT interval prolongation all there is in drug-induced torsadogenesis? A review of emerging trends. J Pharmacol Toxicol Methods 2006;53:87-105.
40. Olson H, Betton G, Robinson D, Thomas K, Monro A, Kolaja G, et al.: Concordance of the toxicity of pharmaceuticals in humans and in animals. Regul Toxicol Pharmacol 2000;32:56-67.
41. Stummann TC, Bremer S: The possible impact of human embryonic stem cells on safety pharmacological and toxicological assessments in drug discovery and drug development. Curr Stem Cell Res Ther 2008;3:117-130.